Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis

J Clin Oncol. 2012 Apr 20;30(12):e126-9. doi: 10.1200/JCO.2011.38.9973. Epub 2012 Feb 27.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Biopsy, Needle
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Follow-Up Studies
  • Humans
  • Imatinib Mesylate
  • Immunohistochemistry
  • Male
  • Mastocytosis, Systemic / drug therapy*
  • Mastocytosis, Systemic / pathology*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Rare Diseases
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate